Last updated: February 13, 2026
What is NDC 00093-0262?
NDC 00093-0262 represents Prevnar 13 (pneumococcal 13-valent conjugate vaccine), manufactured by Pfizer. It is indicated for active immunization to prevent pneumonia, meningitis, and bacteremia caused by Streptococcus pneumoniae in children and adults.
Market Overview
Size and Growth
- The global pneumococcal vaccine market was valued at approximately $6.9 billion in 2022.
- Projected CAGR (Compound Annual Growth Rate) of approximately 7% through 2028.
- Estimated annual sales of Prevnar 13 reached $4.2 billion in 2022 [1].
Key Market Drivers
- Rising incidence of pneumococcal diseases.
- Expanded vaccination recommendations by CDC, ACIP, and WHO.
- Increased vaccination coverage in pediatric and adult populations.
- Growing awareness about vaccine safety and efficacy.
Competitive Landscape
Major competitors include:
- Pfizer's Prevnar 13: Market leader.
- Merck's Vaxneuvance (PCV20): Approved in the U.S. since 2021.
- Other regional vaccines with limited market share.
The introduction of PCV20, covering 20 serotypes, has begun to impact Prevnar 13 sales, especially in adult populations.
Regulatory and Pricing Environment
Pricing Factors
-
List price for Prevnar 13 varies:
- U.S. (Commercial): Approximately $150-$170 per dose.
- Public sector (Medicare/Medicaid): Negotiated discounts, often $80-$120.
-
Federal programs like the CDC's Vaccines for Children (VFC) program purchase at lower prices, impacting net revenue.
Reimbursement and Coverage
- High reimbursement rates in the U.S.
- CMS (Centers for Medicare & Medicaid Services) policies favor vaccine coverage, supporting steady sales.
Price Projections
Short-Term (Next 1-2 Years)
- Anticipated prices will remain stable barring policy changes.
- List prices might increase marginally due to inflation and manufacturing costs.
Mid to Long Term (3-5 Years)
- Entry of PCV20 may reduce Prevnar 13’s pricing power.
- Pfizer could adjust prices downward or maintain discounts to sustain market share.
- Potential for price erosion in public programs due to negotiations and increased competition.
Revenue Outlook
| Period |
Estimated Market Share |
Approximate Revenue (USD) |
Notes |
| 2023 |
60% |
$2.5 billion |
Dominance in pediatric vaccine market |
| 2025 |
50% |
$2.2 billion |
Impact of PCV20 gaining acceptance |
| 2028 |
40% |
$1.8 billion |
Further competition and market saturation |
Future Market Trends
- Adoption of newer conjugate vaccines with broader serotype coverage.
- Expansion into emerging markets, which could grow the overall market.
- Development of combination vaccines targeting multiple pathogens.
Risks and Opportunities
Risks:
- Price erosion due to competition.
- Regulatory delays or restrictions.
- Changes in vaccination guidelines that may reduce demand.
Opportunities:
- Market expansion in developing regions.
- Launch of next-generation vaccines.
- Strategic partnerships for broader distribution.
Key Takeaways
- Prevnar 13 remains a leading vaccine with stable revenue in the near term.
- The entry of PCV20 introduces price competition and potential market share shifts.
- Pricing will be influenced by policy, negotiations, and innovation.
- Market growth depends on expanding vaccination coverage and emerging markets.
- Continued R&D and regulatory efforts are critical to maintaining market position.
FAQs
1. How does the pricing of Prevnar 13 compare globally?
Pricing varies significantly; developed countries typically pay higher list prices, while public programs and emerging markets benefit from negotiated discounts and subsidies.
2. What factors could impact Prevnar 13's market share long-term?
Introduction of broader vaccines like PCV20 and evolving vaccination guidelines are primary factors.
3. How has COVID-19 affected pneumococcal vaccine sales?
Disruptions in healthcare delivery and vaccine demand fluctuations have temporarily impacted sales, but recovery is underway.
4. Are there upcoming patent expirations?
Pfizer's patent protections primarily last until around 2028-2030; generic or biosimilar competition is unlikely in the near future due to vaccine complexity.
5. What opportunities exist in emerging markets?
Growing healthcare infrastructure and vaccination programs can expand Prevnar 13’s reach and sales in Asia, Africa, and Latin America.
References
[1] IQVIA. Global Pneumococcal Vaccine Market Data, 2022.
